Synonym
SU11271; SU11271; SU 11271.
IUPAC/Chemical Name
(Z)-3-((3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl)methylene)-5-(indolin-1-ylsulfonyl)indolin-2-one
InChi Key
MHTSQKQLTZCFPE-QJOMJCCJSA-N
InChi Code
InChI=1S/C29H31N5O4S/c1-18-25(30-19(2)27(18)29(36)33-14-12-32(3)13-15-33)17-23-22-16-21(8-9-24(22)31-28(23)35)39(37,38)34-11-10-20-6-4-5-7-26(20)34/h4-9,16-17,30H,10-15H2,1-3H3,(H,31,35)/b23-17-
SMILES Code
O=C1NC2=C(C=C(S(=O)(N3CCC4=C3C=CC=C4)=O)C=C2)/C1=C/C5=C(C)C(C(N6CCN(C)CC6)=O)=C(C)N5
Appearance
yellow solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
545.65
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1. La Monica, Silvia; Caffarra, Cristina; Saccani, Francesca; Galvani, Elena; Galetti, Maricla; Fumarola, Claudia; Bonelli, Mara; Cavazzoni, Andrea; Cretella, Daniele; Sirangelo, Rita; et al. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification. PLoS One (2013), 8(10), e78656.
2. Golub, Todd; Straussman, Ravid. Methods of treating cancer using a chemotherapeutic agent with an agent that blocks the activity of hepatocyte growth factor or its cognate receptor c-MET. PCT Int. Appl. (2012), WO 2012178038 A1 20121227
3. Wang, Xueyan; Le, Phuong; Liang, Congxin; Chan, Julie; Kiewlich, David; Miller, Todd; Harris, Dave; Sun, Li; Rice, Audie; Vasile, Stefan; et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Molecular Cancer Therapeutics (2003), 2(11), 1085-1092.
